Drugs / CKDB-501A
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05382767 | Jun → Dec 2022 | diplegia of upper limb | CKD Bio Corporation | Completed | No outcome recorded |
| Phase 1 | NCT05292638 | Feb → Jun 2022 | — | CKD Bio Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05804656 | Apr → Aug 2023 | — | CKD Bio Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKDB-501A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05292638 ↗ |
| Modality | Protein / enzyme biologic | “CKDB-501A, a botulinum toxin” PMID 40586136 ↗ Jul 2025 |
| Route | Intramuscular | “Intramuscular injection CKDB-501A” NCT05292638 ↗ |